key: cord-0750835-pvrsv1jo
authors: Mintoff, D.; Scerri, L.; Betts, A.
title: SARS‐CoV‐2 mRNA vaccine injection site pseudolymphoma
date: 2021-09-30
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17680
sha: 2442f93985057568cb55ae047ffa880cb36d1908
doc_id: 750835
cord_uid: pvrsv1jo

A healthy 68-year-old female presented with an erythematous nodule on the outer aspect of her left arm (Figure 1A&B). The location of the nodule coincided with the injection site of the second dose of the Pfizer-BioNTech (Pfizer Inc. New York City, NY, USA) SARS-CoV-2 mRNA vaccine, administered three months before. The nodule was preceded by a pruritic macule which emerged a week after inoculation, and which steadily evolved to the lesion with which the patient presented.

Dear Editor, A healthy 68-year-old female presented with an erythematous nodule on the outer aspect of her left arm (Fig. 1a,b) . The location of the nodule coincided with the injection site of the second dose of the Pfizer-BioNTech (Pfizer, Inc., New York City, NY, USA) SARS-CoV-2 mRNA vaccine, administered three months before. The nodule was preceded by a pruritic macule which emerged a week after inoculation, and which steadily evolved to the lesion with which the patient presented. The patient had not experienced any side effects related to the administration of the first vaccine dose, which she had received 3 weeks before in the ipsilateral arm. Dermoscopic evaluation of the nodule revealed dotted vessels and shiny white lines on an erythematous background.

Histological examination of the excised nodule revealed a wedge-shaped, nodular infiltrate of small mature lymphocytes and rare blasts, extending from the superficial dermis to the subcutis, being denser in the superficial dermis (Fig. 2a) . Occasional lymphocytes extended into the basal layers of the epidermis with associated basal cell vacuolar damage, Civatte body formation and spongiosis, in keeping with an interface (Fig. 2a,b) .

Immunohistochemistry revealed a mixture of B and T cells (Fig. 2c,d) with a predominance of T cells and with a low Ki67 index. The T cells expressed all T cell antigens. No light chain restriction was identified in the B-cells.

Based on clinical and histological features, a diagnosis of cutaneous pseudolymphoma was made.

Vaccination site-associated pseudolymphoma (also referred to as lymphoid hyperplasia and lymphocytoma cutis) is an exceedingly rarealbeit documentedphenomenon. 1 Reactions at the mRNA SARS-CoV-2 injection site have been reported in up to 84.2% of vaccinated patients, with erythema being the commonest. 2 Development of pseudolymphoma at the SARS-CoV-2 injection site is however previously undescribed. The acute or delayed occurrence of cutaneous pseudolymphoma has been reported at the injection site of Hepatitis A, Hepatitis B, 1 quadrivalent human papilloma virus, 3 early summer time meningoencephalitis and tetanus vaccination. 4 Subcutaneous papules, nodules and erythematous patches can be presenting signs of vaccine-associated cutaneous pseudolymphoma. 4 The patient in this case had received various vaccinations throughout her lifetime, including the influenza vaccine on a yearly basis but had not experienced any localized or systemic side effects. It has been proposed that cutaneous pseudolymphoma may represent a reaction to vaccine adjuvants such as aluminium hydroxide. 1 This adjuvant is not found in the Pfizer-BioNtech SARS-CoV-2 mRNA vaccine. 5 By flagging this unique adverse drug reaction, we hope to broaden physician's repertoire of differential diagnoses when presented with SARS-CoV-2-related injection site reactions.

Vaccination-induced cutaneous pseudolymphoma

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Cutaneous pseudolymphoma following quadrivalent human papillomavirus vaccination -a rare adverse event

Cutaneous B-cell pseudolymphoma at the site of vaccination

Vaccine information fact sheet for recipients and caregivers about comirnaty (COVID-19 vaccine, mRNA) and Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)

The patient in this manuscript has given written informed consent to the publication of their case details.

All authors contributed equally to the conceptualizing, drafting and revising of the submitted text.

None of the authors have any relevant conflicts or funding to disclose.

The data that support the finds of this manuscript are available from the corresponding author, DM, upon reasonable request. ). Immunohistochemistry shows a mixture of B and T cells, highlighted by CD3 (c) and CD20 (d) respectively, with a predominance of T cells (x100).